Google Scholar, this publication has been cited 205 times in the literature in just 5 years, demonstrating its impact.
Perhaps seeking to replicate the fame and impact of this landmark study, Dr. Sharma and her colleagues from India utilized an essentially identical study design to evaluate the MAD in children ages 2-14 years with intractable epilepsy. There were some differences compared to the Neal study, primarily in regard to patient demographics: 78% were male, all from a single tertiary center, and a larger percentage (approximately half ) had the diagnosis of Lennox-Gastaut syndrome (2). The study was completed successfully with a lower dropout rate than the Neal study; in fact, with a remarkable 8% discontinuation rate with MAD (versus 15% in the Neal KD study arm) (2) .
The results certainly suggest both a similarity to the KD based on the Neal outcomes, as well as seizure improvement dramatically better than the control. The likelihood of > 50% seizure reduction at 3 months was 52% with the MAD versus 11.5% in the control group. Similarly, > 90% seizure reduction occurred in 30% versus 7.7%. This is similar, if not slightly better, than the Neal findings with the KD, in which they found 38% versus 6% (for > 50% seizure reduction) and 7% versus 0% (> 90% seizure reduction) (2) . These studies can and should not be directly compared, and the high placebo rate in the current study is surprising, yet the results are intriguing. The MAD was very well-tolerated, with adverse effects primarily constipation, weight loss, and vomiting, as would be PURPOSE: The aim of this study was to evaluate the efficacy of the modified Atkins diet in a randomized controlled trial in children with refractory epilepsy. METHODS: Children aged 2-14 years who had daily seizures despite the appropriate use of at least three anticonvulsant drugs were enrolled. Children were randomized to receive either the modified Atkins diet or no dietary intervention for a period of 3 months. The ongoing anticonvulsant medications were continued unchanged in both the groups. Seizure control at 3 months was the primary end point. Analysis was intention to treat. Adverse effects of the diet were assessed by parental reports (ClinicalTrials.gov Identifier: NCT00836836). KEY FINDINGS: Among a total of 102 children, 50 were in the diet group and 52 in the control group. Four children discontinued the diet before the study end point, and three children in the control group were lost to follow-up. The mean seizure frequency at 3 months, expressed as a percentage of the baseline, was significantly less in the diet group: 59 ± 54 (95% confidence interval [CI] 44-74.5) versus 95.5 ± 48 (95% CI 82-109), p = 0.003. The proportion of children with >90% seizure reduction (30% vs. 7.7%, p = 0.005) and >50% seizure reduction was significantly higher in the diet group (52% vs. 11.5%, p < 0.001). Constipation was the most common adverse effect among children on the diet (23, 46%). SIGNIFICANCE: The modified Atkins diet was found to be effective and well tolerated in children with drug-refractory epilepsy.
Ghee Whiz! The Growing Evidence for the Benefits of the Modified Atkins Diet
expected for the KD. Adolescents were reported as having difficulty with the lack of rice and Indian wheat breads (chapattis); no comments were made about their opinions regarding ghee, cream, or oil. There have been prior attempts in India to use less fat and more carbohydrates (e.g., lower ratios) with the classic KD; a cultural taste for carbohydrates clearly exists there (4) .
There are certainly some concerns about the ability to extrapolate these findings, primarily due to the single center in India with some cultural issues (including 44% vegetarian) and a high male percentage. Both this study and the Neal study, although randomized and controlled, had neither a placebo provided nor a blinded assessment. A perhaps more real-world control arm might have been the addition of a new anticonvulsant rather than no change to the current anticonvulsant regimen. However, the results are impressive and add further, now controlled, evidence to the benefits of the MAD.
After a decade of use, the MAD is here to stay. What role in the treatment of epilepsy does this modified ketogenic diet have to play? Most clear at this time is the treatment of adolescents and adults not typically offered the classic ketogenic diet due to its inherent restrictiveness and often need for hospitalization at initiation (5) . From my personal communications, most adult epilepsy diet centers are primarily using the MAD. Dr. Sharma studied children as young as 2 years; however, we would suggest still using the classic KD in those under 10 years. Countries with large populations and limited dietitian availability, such as India, may be ideally suited for the MAD versus the KD, as stated in the Discussion section of this paper by its authors. The MAD has been used successfully in Honduras without dietitian support and can be maintained in adults solely by email, opening up opportunities for global telemedicine to remote regions with sparse resources (6, 7) . Additionally, the MAD may have a unique role in some idiopathic generalized epilepsies that may not be perceived as severe as other etiologies, including absence epilepsy and juvenile myoclonic epilepsy (8, 9) .
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